Experimental evaluation of osteogenic activity of certain hormonal drugs

Introduction: The necessity of extra medicamental stimulation of bone tissue regeneration in addition to basic surgical method of treating fractures is usually determined by osteoporosis or high severity of injury. One of the lesser-studied options for osteogenic hormone therapy of fractures is the use of human chorionic gonadotropin(hCG). The aim of the study: Conducting an experimental evaluation of the osteogenic activity of hCG in its systemic and local application based on a model of perforated fracture of femoral bone in laboratory white rats. Materials and Methods: The experimental perforated femoral fracture in 64 male Wistar laboratory rats was modeled by drilling a circular bone defect with a 1.4 mm diameter. The osteogenic effect of the studied hormonal drugs (hCG and thyrocalcitonin) compared with a reference agent from the bisphosphonate group – zoledronic acid, after a course of injectable treatment was assessed according to the rate of bone defect recovery using digital radiography. In addition, the same method was used to experimentally evaluate the local osteogenic activity of hCGand zoledronate introduced into the bone marrow canal of the damaged bone via a patented original intramedullary metal construction for osteosynthesis. Results and Discussion: Upon administering the studied hormonal drugs by injection, significant osteogenic activity was observed, with a more pronounced effect for hCG, although still inferior to that of the reference pharmacotherapy. The intra-bone local application of hCG showed results practically equal to the osteogenic effect of zoledronate. Conclusion: As a result of the experiment, a high therapeutic effect of hCG on bone tissue regeneration was discovered, which, with local application (intramedullary implants soaked in hCG solution with a concentration of 5000 IU/mL), reached the level of zoledronate’s effect (intramedullary implants soaked in solution with a concentration of 0.8 mg/mL), but without the toxic side effects typically associated with the reference pharmacotherapy.